InstalabLoading...
InstalabLoading...
An antibody that signals past exposure to a nearly universal herpesvirus, with limited ability to reveal whether that virus is currently active.
If you order an HHV-6 IgG (human herpesvirus 6 immunoglobulin G) test, you are almost certainly going to get a positive result. That is not cause for alarm. More than 95% of adults carry antibodies to this virus because nearly everyone is exposed to it before age two. A positive result, on its own, tells you one thing: your immune system has encountered HHV-6 at some point in your life. It does not tell you whether the virus is active right now, whether it is causing symptoms, or whether you need treatment.
This matters because HHV-6, like other herpesviruses, never fully leaves your body after the initial infection. It goes dormant and can reactivate later, especially if your immune system is suppressed. The challenge is that a single IgG blood draw cannot distinguish between a decades-old encounter and a fresh reactivation. That distinction requires either a pair of blood samples drawn weeks apart or a different type of test altogether.
So why does this test exist, and when is it actually useful? The answer depends heavily on context: who you are, what symptoms you have, and whether your immune system is compromised.
The HHV-6 IgG test measures the concentration of a specific antibody your immune system produces in response to HHV-6. IgG antibodies are your body's long-term memory of an infection. Once produced, they typically persist for life. That is why a single positive result reflects exposure history, not current viral activity.
There are a few scenarios where IgG testing becomes more informative. If you have two blood samples drawn weeks apart and the antibody level rises fourfold or more, that pattern suggests either a new infection or a reactivation of the dormant virus. This paired-sample approach is one of the few ways serology can point toward something recent rather than something remote.
In children with a common childhood rash illness called roseola (exanthem subitum), rising IgG levels can help confirm the diagnosis. Children with this illness, including those who develop neurological complications, show clear increases in HHV-6 specific IgG. For adults with healthy immune systems, though, a positive IgG result is expected and rarely changes clinical decisions.
Commercial IgG assays have strong technical performance, with one validated test showing sensitivity of 99.76% and specificity of 98.75%. The issue is not test accuracy. It is that the question the test answers ("have you ever been exposed?") is a different question from the one most people are asking ("is this virus causing my symptoms?").
The clinical picture shifts considerably if your immune system is compromised. For people who have received organ or bone marrow transplants, or who are living with advanced HIV, HHV-6 can reactivate and cause serious problems, including pneumonia, bone marrow failure, brain inflammation, and complications that may threaten the transplant itself.
In these populations, IgG levels carry more weight. A study of bone marrow transplant recipients found that 14 of 20 patients showed increased HHV-6 specific IgG, a pattern consistent with viral reactivation. Separately, research on cord blood transplant recipients found that people with lower antibody levels before transplant had a higher risk of HHV-6 reactivation afterward. If you are preparing for a stem cell transplant, your pre-transplant HHV-6 IgG level may help your medical team anticipate and watch for reactivation.
Even in these higher-risk groups, however, IgG serology alone is not the preferred tool. Quantitative PCR testing, which directly measures the amount of viral DNA in your blood or spinal fluid, is the standard for diagnosing active HHV-6 infection and tracking how well antiviral treatment is working.
Before you interpret any HHV-6 IgG result, there are several confounding factors worth understanding.
Unlike many biomarkers tied to metabolism or inflammation, HHV-6 IgG is not something you can meaningfully raise or lower through diet, exercise, or supplementation. Your level reflects your immune system's historical and ongoing response to a virus that is already living dormantly in your body.
The primary factor that changes HHV-6 IgG levels is immune status. In transplant recipients receiving immunosuppressive medications, the virus can reactivate, and IgG titers may rise in response. Antiviral therapy with agents like ganciclovir or foscarnet can suppress active viral replication, and quantitative PCR is used to monitor treatment response. These treatment decisions are made in close coordination with transplant and infectious disease specialists.
If you are immunocompetent and your result is positive, there is no intervention needed and no established way to change the result. The antibodies are a permanent record of an encounter your immune system successfully managed.